Meiji Licenses JE Vaccine Tech to Serum Institute for 2027 Filing

For biotech and pharma executives, the technology transfer is a classic emerging-market licensing play: a Japanese innovator monetizes a mature vaccine asset through a low-cost global manufacturer. The SII team has already completed technical visits to Japan, reducing the usual due-diligence lead time before a 2027 regulatory filing.

Meiji Seika Pharma announced on August 24, 2026 that it is pursuing a technology collaboration with Serum Institute of India to bring its Japanese encephalitis vaccine to the Indian market. In an exclusive interview with ANI after meeting India's Union Commerce and Industry Minister Piyush Goyal, Meiji President and Representative Director Toshiaki Nagasato confirmed that the company intends to transfer the vaccine technology currently marketed in Japan through its subsidiary KM Biologics to SII. SII technical officials have already visited Japan to study the underlying technology, and SII is expected to apply for Indian regulatory approval as early as next year—2027. If approved, the vaccine would be made available to children in India, according to Nagasato.

“

Meiji Seika Pharma announced on August 24, 2026 that it is pursuing a technology collaboration with Serum Institute of India to bring its Japanese encephalitis vaccine to the Indian market.

Japanese encephalitis is a mosquito-borne viral disease that remains endemic in parts of India, particularly in states like Assam, Uttar Pradesh, Bihar, and West Bengal, where seasonal outbreaks have strained public health systems. India has included JE vaccination in its Universal Immunisation Programme in high-burden districts, but supply reliability and affordability remain central concerns. A technology transfer to SII—the world's largest vaccine manufacturer by volume and a supplier known for some of the lowest production costs globally—could add a locally manufactured JE vaccine option, assuming regulatory bridging data support its use. Nagasato expressed confidence that SII's cost structure would allow the vaccine to be launched at an affordable price.

The partnership builds on Meiji's existing manufacturing presence in India through Medreich Limited, its Bengaluru-based subsidiary. Medreich supplies generic medicines to the UK, Canada, and markets across Europe and Africa, and Nagasato said the company is scaling up production capacity. That operational base could provide regulatory, quality, and supply-chain expertise for Meiji's broader India strategy, even though the JE vaccine itself would be manufactured by SII under technology transfer. Meiji has urged Minister Goyal to help accelerate the approval process, signaling that regulatory timelines—not technology or manufacturing readiness—are the main bottleneck.